Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsStephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
Life of this patent
Estimating the term…
Abstract
The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.
Claims7
An infectious chimeric virus which is a member of the Bunyaviridae family comprising a Bunyaviridae genome, wherein one or both Gc and GN genes of the Bunyaviridae genome is substituted with one or both counterpart Ge and GN genes from a La Crosse virus genome, and wherein the La Crosse virus genome encodes a GN glycoprotein having a mutation at amino acid 148.
Dependencies are inferred from the claim text.